These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 32990026)
1. A view on the landscape of breast cancer brain metastases. Malani R CNS Oncol; 2020 Sep; 9(3):CNS59. PubMed ID: 32990026 [No Abstract] [Full Text] [Related]
2. Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature. Ji G; Zhang C; Guan S; Yao X Clin Breast Cancer; 2018 Oct; 18(5):e759-e765. PubMed ID: 30177482 [No Abstract] [Full Text] [Related]
3. HER2 in brain metastases: issues of concordance, survival, and treatment. Fuchs IB; Loebbecke M; Buhler H; Stoltenburg-Didinger G; Heine B; Lichtenegger W; Schaller G J Clin Oncol; 2002 Oct; 20(19):4130-3. PubMed ID: 12351617 [No Abstract] [Full Text] [Related]
4. The genomic landscape of breast cancer brain metastases: a systematic review. Morgan AJ; Giannoudis A; Palmieri C Lancet Oncol; 2021 Jan; 22(1):e7-e17. PubMed ID: 33387511 [TBL] [Abstract][Full Text] [Related]
5. Emerging strategies for treating brain metastases from breast cancer. Kodack DP; Askoxylakis V; Ferraro GB; Fukumura D; Jain RK Cancer Cell; 2015 Feb; 27(2):163-75. PubMed ID: 25670078 [TBL] [Abstract][Full Text] [Related]
6. Targeted Therapies for Brain Metastases from Breast Cancer. Venur VA; Leone JP Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649142 [TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy in Brain Metastases: Ready for Primetime? Venur VA; Ahluwalia MS Am Soc Clin Oncol Educ Book; 2016; 35():e123-30. PubMed ID: 27249714 [TBL] [Abstract][Full Text] [Related]
8. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109 [TBL] [Abstract][Full Text] [Related]
9. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828 [TBL] [Abstract][Full Text] [Related]
10. Systemic chemotherapeutic treatment of patients with breast cancer brain metastases. Liubota R; Vereshchako R; Anikusko M; Liubota I; Vakulenko G Exp Oncol; 2021 Jun; 43(2):180-184. PubMed ID: 34190516 [TBL] [Abstract][Full Text] [Related]
11. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Wolstenholme V; Hawkins M; Ashley S; Tait D; Ross G Breast; 2008 Dec; 17(6):661-5. PubMed ID: 18571923 [TBL] [Abstract][Full Text] [Related]
12. Targeting HER2 in Advanced Breast Cancer. Zhu X; Joy AA Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634 [TBL] [Abstract][Full Text] [Related]
13. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199 [TBL] [Abstract][Full Text] [Related]
14. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis. Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412 [TBL] [Abstract][Full Text] [Related]
15. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Diossy M; Reiniger L; Sztupinszki Z; Krzystanek M; Timms KM; Neff C; Solimeno C; Pruss D; Eklund AC; Tóth E; Kiss O; Rusz O; Cserni G; Zombori T; Székely B; Kulka J; Tímár J; Csabai I; Szallasi Z Ann Oncol; 2018 Sep; 29(9):1948-1954. PubMed ID: 29917049 [TBL] [Abstract][Full Text] [Related]
16. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312 [TBL] [Abstract][Full Text] [Related]
17. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405 [TBL] [Abstract][Full Text] [Related]
18. Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007. Pegram M; Perez EA; Piccart M; Spector N Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S131-41. PubMed ID: 18777952 [No Abstract] [Full Text] [Related]
20. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Melisko ME; Glantz M; Rugo HS Nat Clin Pract Oncol; 2009 Jan; 6(1):25-33. PubMed ID: 18936791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]